Omeprazole

Brand names: Prilosec · Active ingredient: Omeprazole

In short: Omeprazole delayed-release capsules are indicated for short-term treatment of active duodenal ulcer in adults. Most patients heal within four weeks.

Forms & strengthsOmeprazole delayed-release capsules USP, 20 mg are off-white to pale yellow, spherical, enteric coated pellets filled in size '2' hard gelatin capsule shells with opaque purple colored cap and opaque grey colored body, imprinted 'OMEPRAZOLE' 20 mg on cap and …
LabelProficient Rx LP
Label updatedNov 16, 2026

What is Omeprazole used for?

Omeprazole delayed-release capsules are indicated for short-term treatment of active duodenal ulcer in adults. Most patients heal within four weeks. Some patients may require an additional four weeks of therapy.

Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence.

Triple Therapy

Omeprazole delayed-release capsules in combination with clarithromycin and amoxicillin, are indicated for treatment of patients with H. pylori infection and duodenal ulcer disease (active or up to 1-year history) to eradicate H. pylori in adults.

Dual Therapy

Omeprazole delayed-release capsules in combination with clarithromycin are indicated for treatment of patients with H. pylori infection and duodenal ulcer disease to eradicate H. pylori in adults.

Among patients who fail therapy, omeprazole delayed-release capsules with clarithromycin are more likely to be associated with the development of clarithromycin resistance as compared with triple therapy. In patients who fail therapy, susceptibility testing should be done. If resistance to clarithromycin is demonstrated or susceptibility testing is not possible, alternative antimicrobial therapy should be instituted [see Clinical Pharmacology (12.4) and the clarithromycin prescribing information, Microbiology section].

Omeprazole delayed-release capsules are indicated for short-term treatment (4 to 8 weeks) of active benign gastric ulcer in adults. …

Omeprazole dosage

Table 1 shows the recommended dosage of omeprazole delayed-release capsules in adult patients by indication.

Table 1: Recommended Dosage Regimen of Omeprazole Delayed-Release Capsules in Adults by Indication

Indication | Dosage of Omeprazole Delayed-Release Capsules | Treatment Duration

Treatment of Active Duodenal Ulcer | 20 mg once daily | 4 weeks1

Helicobacter pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence | Triple Therapy Omeprazole delayed-release capsules 20 mg Amoxicillin 1000 mg Clarithromycin 500 mg Take all three drugs twice daily | 10 days In patients with an ulcer present at the time of initiation of therapy, continue omeprazole delayed-release capsules 20 mg once daily for an additional 18 days for ulcer healing and symptom relief.

Dual Therapy Omeprazole delayed-release capsules 40 mg once daily Clarithromycin 500 mg three times daily | 14 days In patients with an ulcer present at the time of initiation of therapy, an additional 14 days of omeprazole delayed-release capsules 20 mg once daily is recommended for ulcer healing and symptom relief.

Active Benign Gastric Ulcer | 40 mg once daily | 4 to 8 weeks

Treatment of Symptomatic GERD | 20 mg once daily | Up to 4 weeks

Treatment of EE due to Acid-Mediated GERD | 20 mg once daily | 4 to 8 weeks2

Maintenance of Healing of EE due to Acid-Mediated GERD | 20 mg once daily3 | Controlled studies do not extend beyond 12 months.

Pathological Hypersecretory Conditions | Starting dose is 60 mg once daily; adjust to patient needs Daily dosages of greater than 80 mg should be administered in divided doses. Dosages up to 120 mg three times daily have been administered. | As long as clinically indicated. Some patients with Zollinger-Ellison syndrome have been treated continuously for more than 5 years.

1. Most patients heal within 4 weeks; some patients may require an additional 4 weeks of therapy to achieve healing

2. The efficacy of omeprazole delayed-release capsules used for longer than 8 weeks in patients with EE has not been established. If a patient does not respond to 8 weeks of treatment, an additional 4 weeks of treatment may be given. If there is recurrence of EE or GERD symptoms (e.g., heartburn), additional 4 to 8 week courses of omeprazole delayed-release capsules may be considered.

3Error! Hyperlink reference not valid. Dosage reduction to 10 mg once daily is recommended for patients with hepatic impairment (Child-Pugh Class A, B or C) and Asian patients when used for the maintenance of healing of EE [see Use in Specific Populations Error! Hyperlink reference not valid.

8.6, 8.7

Error! Hyperlink reference not valid. and Clinical Pharmacology Error! Hyperlink reference not valid.

12.3, 12.5

Error! Hyperlink reference not valid.]. …

How to take Omeprazole — instructions & advice from the label

Advise the patient to read the FDA-approved patient labeling (Medication Guide and Instructions for Use).

Adverse Reactions

Advise patients to report to their healthcare provider if they experience any signs or symptoms consistent with:

• Hypersensitivity reactions .

• Acute Tubulointerstitial Nephritis .

• Clostridium difficile Associated Diarrhea .

• Bone Fracture .

• Cutaneous and Systemic Lupus Erythematosus .

• Cyanocobalamin (Vitamin B-12) Deficiency .

• Hypomagnesemia and Mineral Metabolism .

Drug Interactions

Advise patients to report to their healthcare provider if they start treatment with clopidogrel, St. John’s Wort or rifampin; or, if they take high-dose methotrexate .

Administration

• Take omeprazole delayed-release capsules before meals.

• Antacids may be used concomitantly with omeprazole delayed-release capsules.

• Missed doses: If a dose is missed, administer as soon as possible. However, if the next scheduled dose is due, do not take the missed dose, and take the next dose on time. Do not take two doses at one time to make up for a missed dose.

Omeprazole Delayed-Release Capsules

• Swallow omeprazole delayed-release capsules whole; do not chew. …

Warnings & precautions

Do not take this medicine if: • Omeprazole delayed-release capsules are contraindicated in patients with known hypersensitivity reactions including anaphylaxis to the formulation or any substituted benzimidazole. Hypersensitivity reactions may include anaphylaxis, anaphylactic shock, angioedema, bronchospasm, acute tubulointerstitial nephritis, and urticaria .

• Proton pump inhibitors (PPIs), including omeprazole, are contraindicated in patients receiving rilpivirine-containing products .

• For information about contraindications of antibacterial agents (clarithromycin and amoxicillin) indicated in combination with omeprazole, refer to the CONTRAINDICATIONS section of their package inserts.

In adults, symptomatic response to therapy with omeprazole does not preclude the presence of gastric malignancy. Consider additional follow-up and diagnostic testing in adult patients who have a suboptimal response or an early symptomatic relapse after completing treatment with a PPI. In older patients, also consider an endoscopy.

Acute tubulointerstitial nephritis (TIN) has been observed in patients taking PPIs and may occur at any point during PPI therapy. Patients may present with varying signs and symptoms from symptomatic hypersensitivity reactions, to non-specific symptoms of decreased renal function (e.g., malaise, nausea, anorexia). In reported case series, some patients were diagnosed on biopsy and in the absence of extra-renal manifestations (e.g., fever, rash or arthralgia).

Discontinue omeprazole delayed-release capsules and evaluate patients with suspected acute TIN .

Published observational studies suggest that PPI therapy like omeprazole may be associated with an increased risk of Clostridium difficile-associated diarrhea, especially in hospitalized patients. This diagnosis should be considered for diarrhea that does not improve . …

Omeprazole side effects

The following serious adverse reactions are described below and elsewhere in labeling:

• Acute Tubulointerstitial Nephritis

• Clostridium difficile-Associated Diarrhea

• Bone Fracture

• Cutaneous and Systemic Lupus Erythematosus

• Cyanocobalamin (Vitamin B-12) Deficiency

• Hypomagnesemia and Mineral Metabolism

• Fundic Gland Polyps

Monotherapy

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The safety data described below reflects exposure to omeprazole delayed-release capsules in 3096 patients from worldwide clinical trials (465 patients from U.S. studies and 2,631 patients from international studies). Indications clinically studied in U.S. trials included duodenal ulcer, resistant ulcer, and Zollinger-Ellison syndrome. The international clinical trials were double blind and open-label in design. The most common adverse reactions reported (i.e., with an incidence rate ≥2%) from omeprazole-treated patients enrolled in these studies included headache (7%), abdominal pain (5%), nausea (4%), diarrhea (4%), vomiting (3%), and flatulence (3%). …

Drug interactions

Tables 3 and 4 include drugs with clinically important drug interactions and interaction with diagnostics when administered concomitantly with omeprazole and instructions for preventing or managing them.

Consult the labeling of concomitantly used drugs to obtain further information about interactions with PPIs.

Table 3: Clinically Relevant Interactions Affecting Drugs Co-Administered with Omeprazole and Interaction with Diagnostics

Antiretrovirals

Clinical Impact: | The effect of PPIs on antiretroviral drugs is variable. The clinical importance and the mechanisms behind these interactions are not always known. • Decreased exposure of some antiretroviral drugs (e.g., rilpivirine, atazanavir and nelfinavir) when used concomitantly with omeprazole may reduce antiviral effect and promote the development of drug resistance . • Increased exposure of other antiretroviral drugs (e.g., saquinavir) when used concomitantly with omeprazole may increase toxicity . • There are other antiretroviral drugs which do not result in clinically relevant interactions with omeprazole.

Intervention: | Rilpivirine-containing products: Concomitant use with omeprazole is contraindicated . Atazanavir: Avoid concomitant use with omeprazole. See prescribing information for atazanavir for dosing information. …

About this medicine

The active ingredient in omeprazole delayed-release capsules, USP is a substituted benzimidazole, 5-methoxy-2-[[(4-methoxy-3, 5-dimethyl-2-pyridinyl) methyl] sulfinyl]-1H-benzimidazole, a compound that inhibits gastric acid secretion. Its empirical formula is C17H19N3O3S, with a molecular weight of 345.42. The structural formula is:

Omeprazole USP is a white to off-white powder. Melts between 150°C and 160°C with decomposition. It is soluble in dichloromethane, sparingly soluble in methanol and in alcohol and very slightly soluble in water.

Omeprazole USP is supplied as delayed-release capsules for oral administration. Each delayed-release capsule contains 20 mg of omeprazole in the form of enteric-coated granules with the following inactive ingredients: glyceryl monostearate, hypromellose (5cps), meglumine, methacrylic acid copolymer, poloxamer, sugar globules, talc, titanium dioxide, and triethyl citrate. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID c5e3a37a-f6e3-43d4-a8a9-54db6c271908. Read the full official label on DailyMed.

Related medicines

Pantoprazole Fluoxetine Amoxicillin Famotidine Ondansetron Esomeprazole Docusate Polyethylene Glycol 3350